Philadelphia-positive acute lymphoblastic leukemia in a case of MPL p.(W515L) variant essential thrombocythemia: case report and literature review

References

• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–2405. Epub 2016/ 04/14. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev 2016;30:453–459. Epub 2016/ 06/28. doi:10.1016/j.blre.2016.06.001
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:1599–1613. Epub 2020/ 09/26. doi:10.1002/ajh.26008
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 2018;8:15. Epub 2018/ 02/11. doi:10.1038/s41408-018-0054-y
   PubMed Web of Science ®Google Scholar
• Zoi K, Cross NC. Genomics of myeloproliferative neoplasms. J Clin Oncol 2017;35:947–954. Epub 2017/ 03/16. doi:10.1200/JCO.2016.70.7968
   PubMed Web of Science ®Google Scholar
• Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, Gangat N, Tefferi A. MPL-mutated essential thrombocythemia: a morphologic reappraisal. Blood Cancer J 2018;8:121. Epub 2018/ 11/22. doi:10.1038/s41408-018-0159-3
   PubMed Web of Science ®Google Scholar
• Grabek J, Straube J, Bywater M, Lane SW. MPN: the molecular drivers of disease initiation, progression and transformation and their effect on treatment. Cells 2020;9;1901. Epub 2020/ 08/23. doi:10.3390/cells9081901
   PubMed Web of Science ®Google Scholar
• Haider M, Elala YC, Gangat N, Hanson CA, Tefferi A. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J 2016;6:e487. Epub 2016/ 10/22. doi:10.1038/bcj.2016.98
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507–2513. quiz 2615. Epub 2014/ 07/20. doi:10.1182/blood-2014-05-579136
   PubMed Web of Science ®Google Scholar
• Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc 2017;92:1118–1128. Epub 2017/ 07/10. doi:10.1016/j.mayocp.2017.05.010
   PubMed Web of Science ®Google Scholar
• Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood 2020;136:61–70. Epub 2020/ 05/21. doi:10.1182/blood.2019000943
   PubMed Web of Science ®Google Scholar
• Jaitly V, Wang W. B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera. Blood 2018;131:941. Epub 2018/ 02/24. doi:10.1182/blood-2017-11-819581
   PubMed Web of Science ®Google Scholar
• Gawel WB, Helbig G, Boral K, Kyrcz-Krzemien S. Acute lymphoblastic leukemia transformation in polycythemia vera: a rare phenomenon. Indian J Hematol Blood Transfus 2016;32:62–65. Epub 2016/ 07/14. doi:10.1007/s12288-016-0673-z
   PubMed Web of Science ®Google Scholar
• Wu D, Ye B, Shen J, Peng L, Zhong Z, Zhou Y. Acute lymphoblastic leukemia in the course of polycythemia vera: a case report and review of literature. Indian J Hematol Blood Transfus 2016;32:50–55. Epub 2016/ 07/14. doi:10.1007/s12288-015-0598-y
   PubMed Web of Science ®Google Scholar
• Hilal T, Conley CR. B-cell acute lymphoblastic leukemia with +der(1)t(1;19) (p13;p13.1) arising in the setting of CALR exon 9 mutated essential thrombocythemia. Cancer Genet 2017;218-219:81–83. Epub 2017/ 11/21. doi:10.1016/j.cancergen.2017.10.001
   PubMed Web of Science ®Google Scholar
• Nagai Y, Kawahara M, Sugino N, Shimazu Y, Hishizawa M, Yamashita K, Kadowaki N, Takaori-Kondo A. A case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation. Exp Hematol Oncol 2014;3:6. Epub 2014/ 02/18. doi:10.1186/2162-3619-3-6
   PubMedGoogle Scholar
• Shaheen SP 2nd, Talwalkar SS, Simons R, Yam L. Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature. Arch Pathol Lab Med 2005;129:96–99. Epub 2005/ 01/05. doi:10.5858/2005-129-96-ALLTIA
   PubMed Web of Science ®Google Scholar
• Jurisic V, Colovic N, Terzic T, Djordjevic V, Colovic M. Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature. Pathol Res Pract 2012;208:420–423. Epub 2012/ 06/05. doi:10.1016/j.prp.2012.04.007
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Masala G, Antonioli E, Chiara Susini M, Guglielmelli P, Pieri L, Maggi L, Caini S, Palli D, Bogani C, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009;18:2068–2073. Epub 2009/ 06/18. doi:10.1158/1055-9965.EPI-09-0353
   PubMed Web of Science ®Google Scholar
• Salama ME, Swierczek SI, Tashi T, Warby CA, Reading NS, Prchal JT. Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. Blood 2014;124:1691–1692. Epub 2014/ 09/06. doi:10.1182/blood-2014-04-568410
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017;129:667–679. Epub 2016/ 12/29. doi:10.1182/blood-2016-10-695940
   PubMed Web of Science ®Google Scholar
• Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med 2020;10(2):a034876. 10.Epub 2019/09/25. doi:10.1101/cshperspect.a034876
   PubMed Web of Science ®Google Scholar
• Ravandi F. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2019;133:130–136. Epub 2018/ 11/18. doi:10.1182/blood-2018-08-832105
   PubMed Web of Science ®Google Scholar
• El Fakih R, Jabbour E, Ravandi F, Hassanein M, Anjum F, Ahmed S, Kantarjian H. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol 2018;93:286–295. Epub 2017/ 10/04. doi:10.1002/ajh.24926
   PubMed Web of Science ®Google Scholar
• Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Y, Jin J, Jiang H, et al. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: a Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clin Cancer Res 2021;27:70–77. Epub 2020/ 09/16. doi:10.1158/1078-0432.CCR-20-1600
   PubMed Web of Science ®Google Scholar
• Anastasi J, Pettenati MJ, Le Beau MM, Kwaan HC, Weil SC. Acute lymphoblastic leukemia in a patient with longstanding polycythemia vera: cytogenetic analysis reveals two distinct abnormal clones. Am J Hematol 1988;29:33–37. Epub 1988/ 09/01. doi:10.1002/ajh.2830290108
   PubMed Web of Science ®Google Scholar
• Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma 2012;53:1839–1841. Epub 2012/ 02/07. doi:10.3109/10428194.2012.663916
   PubMed Web of Science ®Google Scholar
• Tao J, Zhang X, Lancet J, Bennett JM, Cai L, Papenhausen P, Moscinski L, Zhang L. Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation. Cancer Genet 2014;207:489–494. Epub 2014/ 12/03. doi:10.1016/j.cancergen.2014.10.001
   PubMed Web of Science ®Google Scholar
• Langabeer SE, Haslam K, O’Brien D, Kelly J, Andrews C, Ryan C, Flavin R, Hayden PJ, Bacon CL. Acute lymphoblastic leukemia arising in CALR mutated essential thrombocythemia. Case Rep Hematol 2016;2016:6545861. Epub 2016/ 02/24. doi:10.1155/2016/6545861
   PubMed Web of Science ®Google Scholar
• Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood 2015;125:327–335. Epub 2014/ 10/05. doi:10.1182/blood-2014-04-567024
   PubMed Web of Science ®Google Scholar
• Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 2015;125:304–315. Epub 2014/ 11/15. doi:10.1182/blood-2014-04-555508
   PubMed Web of Science ®Google Scholar
• Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25–38. Epub 2011/ 07/05. doi:10.1016/j.ccr.2011.06.003
   PubMed Web of Science ®Google Scholar
• Feng J, Li Y, Jia Y, Fang Q, Gong X, Dong X, Ru K, Li Q, Zhao X, Liu K, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol 2017;10:61. Epub 2017/ 03/02. doi:10.1186/s13045-017-0431-1
   PubMed Web of Science ®Google Scholar
• Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, et al. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nat Commun 2017;8:15102. Epub 2017/ 04/26. doi:10.1038/ncomms15102
   PubMed Web of Science ®Google Scholar
• Li R, Zhou Y, Cao Z, Liu L, Wang J, Chen Z, Xing W, Chen S, Bai J, Yuan W, et al. TET2 loss dysregulates the behavior of bone marrow mesenchymal stromal cells and accelerates Tet2(-/-)-driven myeloid malignancy progression. Stem Cell Rep 2018;10:166–179. Epub 2018/ 01/02. doi:10.1016/j.stemcr.2017.11.019
   PubMed Web of Science ®Google Scholar
• Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118:4509–4518. Epub 2011/ 08/02. doi:10.1182/blood-2010-12-325241
   PubMed Web of Science ®Google Scholar
• Larson RA. Is there a best TKI for chronic phase CML? Blood 2015;126:2370–2375. Epub 2015/ 11/21. doi:10.1182/blood-2015-06-641043
   PubMed Web of Science ®Google Scholar